15 November 2025, Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics" hereafter, HKEX code: 02256.HK) today announced that the company’s Founder and Chief Executive Officer, Dr. Yao-Chang Xu, along with Head of Business Development, Mr. Roger Xu, have been invited to attend the 2025 Jefferies Global Healthcare Conference. The conference will be held from November 17 to 20, 2025, in Landon, UK.

The Jefferies Global Healthcare Conference is recognized as one of the world’s most influential healthcare investment events. It brings together C-Suite executives from leading global healthcare companies, institutional investors, private equity and venture capital firms to explore industry trends and collaboration opportunities. In 2024, the conference attracted over 700 healthcare companies, 3,600 attendees, and 10,000 investor and business-to-business meetings.

During the conference, Dr. Yao-Chang Xu, Founder and CEO of Abbisko, and Mr. Roger Xu, Head of Business Development, will engage in in-depth discussions with global investors and potential partners, sharing the company’s latest progress in innovative drug development, global strategic expansion, and commercialization efforts, and exploring opportunities for future collaboration.

For partnership or investment inquiries, please contact:

Business Development: BD@abbisko.com

Investor Relations: IR@abbisko.com

About Abbisko Therapeutics

Founded in April 2016, Abbisko Therapeutics Co., Ltd. (HKEX: 02256.HK), is an oncology-focused biopharmaceutical company based in Shanghai that is dedicated to the discovery and development of innovative medicines to treat unmet medical needs in China and globally. The Company was established by a group of seasoned drug hunters with rich research & development and managerial expertise from top multinational pharmaceutical companies. Since its founding, Abbisko Therapeutics has built an extensive pipeline of innovative programs focused on precision oncology and immuno-oncology.

Please visit www.abbisko.com for more information.